Consensus AbbVie Inc.

Stocks

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - NYSE 16:03:57 2026-09-18 EDT			5-day change	1st Jan Change
263.96 ^USD	-0.02%		+2.66%	+15.52%

09-18	AbbVie Presents New Real-World Data Supporting Effectiveness of VRAYLAR (Cariprazine) At Psych Congress 2026	CI
09-17	US regulators urge more research on testosterone therapy for women as experts debate benefits, risks	RE

Evolution of the Average Target: AbbVie Inc.

Evolution of the Target Price: AbbVie Inc.

Changes in Analyst Recommendations: AbbVie Inc.

48f97efe5b048ff151.MSI8LhmkAgbAZQyth1V3XdriZQCxuOdI1hQD1-lFd7c.f1tMeWjGOnzyPWDlwBQuEJfRDEnTyNMloX905KIsMMJlV3NfVdRPf4UIWQ~68b615f978b163d25178051632649b66

Analysts' recommendations: AbbVie Inc.

09-10	HSBC Adjusts Price Target on AbbVie to $315 From $300, Keeps Buy Rating	MT
09-08	BofA Securities Adjusts Price Target on AbbVie to $282 From $276	MT
08-20	Piper Sandler Adjusts Price Target on AbbVie to $303 From $298, Maintains Overweight Rating	MT
08-17	Wells Fargo Adjusts Price Target on AbbVie to $300 From $295, Keeps Overweight Rating	MT
08-13	Wolfe Upgrades AbbVie to Outperform From Peer Perform, Price Target is $300	MT
08-11	BNP Paribas Adjusts Price Target on AbbVie to $247 From $218, Maintains Neutral Rating	MT
08-05	Argus Lifts AbbVie Price Target to $270 From $250	MT
08-05	Leerink Partners Adjusts Price Target on AbbVie to $279 From $245	MT
08-04	Guggenheim Adjusts Price Target on AbbVie to $288 From $261, Maintains Buy Rating	MT
08-04	Rothschild & Co Redburn Adjusts Price Target on AbbVie to $285 From $284, Maintains Buy Rating	MT
08-03	AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says	MT
08-03	Oppenheimer Adjusts AbbVie Price Target to $258 From $244, Maintains Neutral Rating	MT
08-03	Canaccord Genuity Adjusts AbbVie Price Target to $290 From $282, Maintains Buy Rating	MT
07-31	JPMorgan Adjusts Price Target on AbbVie to $285 From $280	MT
07-28	Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating	MT
07-22	Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating	MT
07-15	Citigroup Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating	MT
07-13	BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating	MT
07-13	UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating	MT
07-10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT
07-10	BofA Securities Adjusts AbbVie Price Target to $276 From $234	MT
07-10	AbbVie's Q2 Results Expected to be Inline With Expectations, RBC Says	MT
07-10	RBC Raises Price Target on AbbVie to $280 From $260, Keeps Outperform Rating	MT
07-10	Wells Fargo Adjusts Price Target on AbbVie to $295 From $260	MT
07-09	JPMorgan Adjusts Price Target on AbbVie to $280 From $260	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ABBVIE INC.					+5.55%
	ELI LILLY AND COMPANY					+14.96%
	JOHNSON & JOHNSON					+2.93%
	ROCHE HOLDING AG					+5.2%
	NOVARTIS AG					+9.33%
	ASTRAZENECA PLC					+26.44%
	AMGEN INC.					+0.53%
	NOVO NORDISK A/S					+10.16%
	GILEAD SCIENCES, INC.					+5.35%
	PFIZER INC.					+4.39%
	Average					+8.48%
	Weighted average by Cap.					+9.24%